mhc class ii

Anti-Mouse MHC Class II (β chain) Antibody (KL277) is an IgG antibody inhibitor sourced from hamster or mouse and targets mouse MHC Class II.

Anti-Mouse MHC class II (I-A) Antibody (Y-3P) is an IgG2a, κ inhibitory antibody derived from mice and targets mouse MHC class II proteins.

Anti-Mouse MHC Class II (I-Ak, I-Ar, I-Af, I-As, I-Ag7) Antibody (10-3.6.2) is an IgG2c, κ antibody inhibitor derived from mice, targeting murine MHC Class II molecules.

Anti-Mouse/Rat MHC Class II (I-Ek/RT1-D) Antibody (14-4-4S) is an IgG2a, κ antibody inhibitor derived from mice, designed to target MHC Class II in both mice and rats.

Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) is an IgG2b antibody inhibitor derived from rats, specifically targeting mouse MHC Class II.

Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is an IgG2a, κ antibody inhibitor derived from mice that targets monkey or human MHC class II.

Eftilagimod alfa (IMP321), a recombinant LAG-3Ig fusion protein, binds to MHC class II and mediates the activation of antigen-presenting cells (APCs), which in turn activates CD8 T-cells. It is utilized in the research of metastatic melanoma and metastatic breast carcinoma [1].

Favezelimab (MK-4280), a humanized monoclonal antibody directed against LAG-3, inhibits the molecular interaction between LAG-3 and its ligand MHC class II, thereby restoring T-cell function. Favezelimab (MK-4280) has been evaluated as a candidate for colorectal cancer (CRC) research, particularly in studies that investigate synergistic effects in combination with the PD-L1 inhibitor Pembrolizumab .

Encelimab, an anti-LAG3 monoclonal antibody, prevents the interaction between LAG-3 and MHC class II molecules, thereby facilitating the activation of T-cells and promoting an enhanced anti-tumor immune response. Encelimab demonstrates efficacy in preclinical models, as it has been observed to reduce tumor burden when administered either as a monotherapy or in conjunction with an anti-PD-1 antibody in lymphoma mouse models, specifically the A20 cell xenograft model.